StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
H.C. Wainwright Reiterates Buy Rating on Vanda Pharmaceuticals (VNDA)
June 4, 2026 6:42 AM
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $21.00 price target on Vanda Pharmaceuticals (NASDAQ: VNDA).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
